A safety audit of the first 10 000 intravitreal ranibizumab injections performed by nurse practitioners

Eye (Basingstoke)

Volumn 28, Issue 10, 2014, Pages 1161-1164

  Simcock, P ^a   Kingett, B ^a   Mann, N ^a   Reddy, V ^a   Park, J ^a  

^a ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; BLURRED VISION; CONJUNCTIVAL HEMORRHAGE; DRUG SAFETY; ENDOPHTHALMITIS; EYE DISCOMFORT; FEMALE; HUMAN; INJECTION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MIDDLE AGED; NURSE PRACTITIONER; PATIENT SAFETY; PROSPECTIVE STUDY; RETINA DETACHMENT; THROMBOEMBOLISM; VERY ELDERLY; VISUAL ACUITY;

EID: 84927688485     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2014.153     Document Type: Article

References (11)

1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovasculqar age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
2. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab versus Verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
3. Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 2008; 12: iii-iv ix-201.
4. Owen CG, Jarrar Z, Wormald R, Cook DG, Gletcher AE, Rudnicka AR. The estimated prevalence and incidence of late stage age-related macular degeneration in the UK. Br J Ophthalmol 2012; 96: 752-756.
5. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143: 566-583.
6. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009; 148: 43-58.
7. Lyall DAM, Tey A, Foot B, Roxburgh STD, Virdi M, Robertson C et al. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes. Eye 2012; 26: 1517-1526.
8. Saeed MU, Prasad S. Management of cataract caused by inadvertent capsule penetration during intravitreal injection of ranibizumab. J Cataract Refract Surg 2009; 35: 1857-1859.
9. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular oedema. Ophthalmology 2010; 117: 1064-1077.
10. Brown DM, Campochiaro PA, Sing RP, Li Z, Gray S, Saroj N et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1124-1133.
11. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1102-1112.